British Journal of Cancer

Article	Citations
Deep learning in cancer pathology: a new generation of clinical biomarkers	357
The lingering mysteries of metastatic recurrence in breast cancer	314
Achieving clinical success with BET inhibitors as anti-cancer agents	234
Breast cancer as an example of tumour heterogeneity and tumour cell plasticity during malignant progression	226
Fibroblast growth factor receptors in cancer: genetic alterations, diagnostics, therapeutic targets and mechanisms of resistance	188
Insights into the role of sialylation in cancer progression and metastasis	172
Tumour treating fields therapy for glioblastoma: current advances and future directions	166
Treatment strategies for breast cancer brain metastases	142
Mutational drivers of cancer cell migration and invasion	140
Promises and challenges of adoptive T-cell therapies for solid tumours	136
EMTome: a resource for pan-cancer analysis of epithelial-mesenchymal transition genes and signatures	135
Cysteine metabolic circuitries: druggable targets in cancer	128
Radiomics and radiogenomics in gliomas: a contemporary update	113
The effect of geriatric intervention in frail older patients receiving chemotherapy for colorectal cancer: a randomised trial (GERICO)	108
Artificial intelligence in oncology: current applications and future perspectives	102
Endocytosis: a pivotal pathway for regulating metastasis	96
Cell-free DNA analysis in current cancer clinical trials: a review	95
Metabolic reprogramming in prostate cancer	94
Cancer immunotherapy: it’s time to better predict patients’ response	92
Fibroblast growth factor receptor 3 alterations and response to immune checkpoint inhibition in metastatic urothelial cancer: a real world experience	88
Biomarkers of response to PD-1 pathway blockade	88
FOLFIRI plus cetuximab or bevacizumab for advanced colorectal cancer: final survival and per-protocol analysis of FIRE-3, a randomised clinical trial	87
The gut microbiome: what the oncologist ought to know	85
Artificial Intelligence-based methods in head and neck cancer diagnosis: an overview	83
Anlotinib vs placebo as third- or further-line treatment for patients with small cell lung cancer: a randomised, double-blind, placebo-controlled Phase 2 study	82

The COVID-19 pandemic and impact on breast cancer diagnoses: what happened in England in the first half of 2020	80
A phase 1b randomised, placebo-controlled trial of nabiximols cannabinoid oromucosal spray with temozolomide in patients with recurrent glioblastoma	77
Raman spectroscopy: current applications in breast cancer diagnosis, challenges and future prospects	76
Towards decoding the coupled decision-making of metabolism and epithelial-to-mesenchymal transition in cancer	74
Tumour-infiltrating lymphocytes: from prognosis to treatment selection	73
Pan-cancer association of HLA gene expression with cancer prognosis and immunotherapy efficacy	73
Phase 1 study of single-agent WNT974, a first-in-class Porcupine inhibitor, in patients with advanced solid tumours	71
A first-in-man phase 1 study of the DNA-dependent protein kinase inhibitor peposertib (formerly M3814) in patients with advanced solid tumours	71
A Phase 1 study of RO6870810, a novel bromodomain and extra-terminal protein inhibitor, in patients with NUT carcinoma, other solid tumours, or diffuse large B-cell lymphoma	71
Phase 1 study of the ATR inhibitor berzosertib (formerly M6620, VX-970) combined with gemcitabine ± cisplatin in patients with advanced solid tumours	71
Severity of COVID-19 in children with cancer: Report from the United Kingdom Paediatric Coronavirus Cancer Monitoring Project	68
Prognostic value of desmoplastic reaction characterisation in stage II colon cancer: prospective validation in a Phase 3 study (SACURA Trial)	65
Long non-coding RNAs are involved in alternative splicing and promote cancer progression	65
Cannabinoids as anticancer drugs: current status of preclinical research	65
The current treatment landscape in the UK for stage III NSCLC	64
The mental health impacts of receiving a breast cancer diagnosis: A meta-analysis	64
The current status of risk-stratified breast screening	64
Roles of mitochondria in the hallmarks of metastasis	64
Cancer cachexia: a nutritional or a systemic inflammatory syndrome?	64
ESR1 mutations and therapeutic resistance in metastatic breast cancer: progress and remaining challenges	63
Fusobacterium nucleatum confers chemoresistance by modulating autophagy in oesophageal squamous cell carcinoma	62
Adoption of artificial intelligence in breast imaging: evaluation, ethical constraints and limitations	61
Overcoming the challenges associated with CD3+ T-cell redirection in cancer	60
Vascular normalisation as the stepping stone into tumour microenvironment transformation	59
Detection of clustered circulating tumour cells in early breast cancer	57
Non-coding RNAs as liquid biopsy biomarkers in cancer	57
Breast cancer brain metastasis: insight into molecular mechanisms and therapeutic strategies	56
UK Biobank: a globally important resource for cancer research	56
Cancer metastasis as a non-healing wound	56
Prognostic refinement of NSMP high-risk endometrial cancers using oestrogen receptor immunohistochemistry	54
Extracellular vesicles as a source of prostate cancer biomarkers in liquid biopsies: a decade of research	53
Effects of cancer screening restart strategies after COVID-19 disruption	52
Cancer-inducing niche: the force of chronic inflammation	52
The fibrotic and immune microenvironments as targetable drivers of metastasis	51
Liquid biopsy and non-small cell lung cancer: are we looking at the tip of the iceberg?	51
Is it still worth pursuing the repurposing of metformin as a cancer therapeutic?	51
Targeting NQO1/GPX4-mediated ferroptosis by plumbagin suppresses in vitro and in vivo glioma growth	50
Integrating circulating-free DNA (cfDNA) analysis into clinical practice: opportunities and challenges	49
Liquid biopsies to monitor and direct cancer treatment in colorectal cancer	49
Advances in the curative management of oesophageal cancer	49
Estimating the population health impact of a multi-cancer early detection genomic blood test to complement existing screening in the US and UK	48
Diagnostic performance of a faecal immunochemical test for patients with low-risk symptoms of colorectal cancer in primary care: an evaluation in the South West of England	48
Postoperative, but not preoperative, inflammation-based prognostic markers are prognostic factors in stage III colorectal cancer patients	47
Tertiary lymphoid structure score: a promising approach to refine the TNM staging in resected non-small cell lung cancer	47
Functional analysis of circulating tumour cells: the KEY to understand the biology of the metastatic cascade	46
Human papilloma virus (HPV) integration signature in Cervical Cancer: identification of MACROD2 gene as HPV hot spot integration site	46
Serum alpha-fetoprotein and clinical outcomes in patients with advanced hepatocellular carcinoma treated with ramucirumab	46
At the dawn: cell-free DNA fragmentomics and gene regulation	46
Squeezing through the microcirculation: survival adaptations of circulating tumour cells to seed metastasis	46
Tumour acidosis evaluated in vivo by MRI-CEST pH imaging reveals breast cancer metastatic potential	45

Liquid BIOpsy for MiNimal RESidual DiSease Detection in Head and Neck Squamous Cell Carcinoma (LIONESS)—a personalised circulating tumour DNA analysis in head and neck squamous cell carcinoma	44
Evolving landscape of PD-L2: bring new light to checkpoint immunotherapy	44
SLFN11 informs on standard of care and novel treatments in a wide range of cancer models	44
Mitochondrial oxidative phosphorylation in cutaneous melanoma	44
COVID-19 and cancer registries: learning from the first peak of the SARS-CoV-2 pandemic	43
Differences in cancer incidence by broad ethnic group in England, 2013–2017	43
Bone marrow niches in the regulation of bone metastasis	42
Infiltrating T-cell markers in cervical carcinogenesis: a systematic review and meta-analysis	42
Histopathological growth patterns of liver metastasis: updated consensus guidelines for pattern scoring, perspectives and recent mechanistic insights	41
Comparative analysis of drug response and gene profiling of HER2-targeted tyrosine kinase inhibitors	41
Phase 1 study of the ATR inhibitor berzosertib in combination with cisplatin in patients with advanced solid tumours	41
Offering HPV self-sampling kits: an updated meta-analysis of the effectiveness of strategies to increase participation in cervical cancer screening	41
Nintedanib promotes antitumour immunity and shows antitumour activity in combination with PD-1 blockade in mice: potential role of cancer-associated fibroblasts	41
Identifying optimal first-line treatment for advanced non-small cell lung carcinoma with high PD-L1 expression: a matter of debate	41
An urgent call to raise the bar in oncology	40
Recovery strategies following COVID-19 disruption to cervical cancer screening and their impact on excess diagnoses	40
Multicenter evaluation of breast cancer patients’ satisfaction and experience with oncology telemedicine visits during the COVID-19 pandemic	40
Endogenous hormones and risk of invasive breast cancer in pre- and post-menopausal women: findings from the UK Biobank	40
Emerging immunotherapies for metastasis	40
Ultra-processed foods and cancer risk: from global food systems to individual exposures and mechanisms	40
Efficacy of first-line atezolizumab combination therapy in patients with non-small cell lung cancer receiving proton pump inhibitors: post hoc analysis of IMpower150	40
The risk of contralateral breast cancer: a SEER-based analysis	39
Ferroptosis in hepatocellular carcinoma: mechanisms and targeted therapy	39
Circulating tumour cells in the -omics era: how far are we from achieving the ‘singularity’?	39
Exosomal protein angiopoietin-like 4 mediated radioresistance of lung cancer by inhibiting ferroptosis under hypoxic microenvironment	39
MicroRNAs as biomarkers for prostate cancer prognosis: a systematic review and a systematic reanalysis of public data	39
Mammographic microcalcifications and risk of breast cancer	39
Mapping of truncated O-glycans in cancers of epithelial and non-epithelial origin	38
Clinical biomarker-based biological aging and risk of cancer in the UK Biobank	38
EEF1A2 interacts with HSP90AB1 to promote lung adenocarcinoma metastasis via enhancing TGF-β/SMAD signalling	38
Risk of COVID-19 death in cancer patients: an analysis from Guy’s Cancer Centre and King’s College Hospital in London	38
RNA modifications in cancer	37
Blood-based liquid biopsies for prostate cancer: clinical opportunities and challenges	37
Genomic landscape of pleural and peritoneal mesothelioma tumours	36
IL-10 in glioma	36
SLC38A4 functions as a tumour suppressor in hepatocellular carcinoma through modulating Wnt/β-catenin/MYC/HMGCS2 axis	36
50 years on and still very much alive: ‘Apoptosis: a basic biological phenomenon with wide-ranging implications in tissue kinetics’	36
Pancreatic cancer cachexia: three dimensions of a complex syndrome	36
Toll-like receptor 9 agonists and combination therapies: strategies to modulate the tumour immune microenvironment for systemic anti-tumour immunity	36
Determining lines of therapy in patients with solid cancers: a proposed new systematic and comprehensive framework	35
Clinical utility of circulating tumour cell-based monitoring of late-line chemotherapy for metastatic breast cancer: the randomised CirCe01 trial	35
Safety and impact of dose reductions on efficacy in the randomised MONALEESA-2, -3 and -7 trials in hormone receptor-positive, HER2-negative advanced breast cancer	35
Pathological features of 11,337 patients with primary ductal carcinoma in situ (DCIS) and subsequent events: results from the UK Sloane Project	35
Cancer survivorship, excess body fatness and weight-loss intervention—where are we in 2020?	35
Incidence trends for twelve cancers in younger adults—a rapid review	34
CCT5 induces epithelial-mesenchymal transition to promote gastric cancer lymph node metastasis by activating the Wnt/β-catenin signalling pathway	34
CD8+ T cells inhibit metastasis and CXCL4 regulates its function	34
Tumour neoantigen mimicry by microbial species in cancer immunotherapy	34
Fruit and vegetable consumption and incident breast cancer: a systematic review and meta-analysis of prospective studies	34
Serum lipid profiles and risk of colorectal cancer: a prospective cohort study in the UK Biobank	33
Resistance to immune checkpoint inhibitors in advanced gastro-oesophageal cancers	33
Deletion of the deISGylating enzyme USP18 enhances tumour cell antigenicity and radiosensitivity	33
Challenges in glioblastoma immunotherapy: mechanisms of resistance and therapeutic approaches to overcome them	33
The role of Schlafen 11 (SLFN11) as a predictive biomarker for targeting the DNA damage response	33
UCHL1 as a novel target in breast cancer: emerging insights from cell and chemical biology	32
New clinical and biological insights from the international TARGIT-A randomised trial of targeted intraoperative radiotherapy during lumpectomy for breast cancer	32
Modelling immune cytotoxicity for cholangiocarcinoma with tumour-derived organoids and effector T cells	32
CXCL9 inhibits tumour growth and drives anti-PD-L1 therapy in ovarian cancer	32
Porphyromonas gingivalis infection exacerbates oesophageal cancer and promotes resistance to neoadjuvant chemotherapy	32
Expression and functions of long non-coding RNA NEAT1 and isoforms in breast cancer	32
Investigation of circulating metabolites associated with breast cancer risk by untargeted metabolomics: a case–control study nested within the French E3N cohort	32
Comparative performance of lung cancer risk models to define lung screening eligibility in the United Kingdom	32
Characterisation of circulating tumour cell phenotypes identifies a partial-EMT sub-population for clinical stratification of pancreatic cancer	32
The projected impact of the COVID-19 lockdown on breast cancer deaths in England due to the cessation of population screening: a national estimation	32
Oral antibiotic use and early-onset colorectal cancer: findings from a case-control study using a national clinical database	32
Inhibition of interferon-signalling halts cancer-associated fibroblast-dependent protection of breast cancer cells from chemotherapy	32
Preventive effect of sensorimotor exercise and resistance training on chemotherapy-induced peripheral neuropathy: a randomised-controlled trial	31
COVID-19 vaccine race: watch your step for cancer patients	31
Development of an AI system for accurately diagnose hepatocellular carcinoma from computed tomography imaging data	31
Genomic control of metastasis	31
Novel evidence for m6A methylation regulators as prognostic biomarkers and FTO as a potential therapeutic target in gastric cancer	31
Dual [68Ga]DOTATATE and [18F]FDG PET/CT in patients with metastatic gastroenteropancreatic neuroendocrine neoplasms: a multicentre validation of the NETPET score	30
High-dimensional role of AI and machine learning in cancer research	30
Metastasis: crosstalk between tissue mechanics and tumour cell plasticity	30
Peritoneal metastases from colorectal cancer belong to Consensus Molecular Subtype 4 and are sensitised to oxaliplatin by inhibiting reducing capacity	30
Bridging The Age Gap: observational cohort study of effects of chemotherapy and trastuzumab on recurrence, survival and quality of life in older women with early breast cancer	30
The emerging role of PI3K inhibitors for solid tumour treatment and beyond	30
miR-199b-5p-DDR1-ERK signalling axis suppresses prostate cancer metastasis via inhibiting epithelial-mesenchymal transition	30
Density and maturity of peritumoral tertiary lymphoid structures in oesophageal squamous cell carcinoma predicts patient survival and response to immune checkpoint inhibitors	29
Schlafen 11 predicts response to platinum-based chemotherapy in gastric cancers	29

The RNA polymerase I transcription inhibitor CX-5461 cooperates with topoisomerase 1 inhibition by enhancing the DNA damage response in homologous recombination-proficient high-grade serous ovarian ca	29
TP53 mutations increase radioresistance in rhabdomyosarcoma and Ewing sarcoma	29
A wake-up call for cancer DNA damage: the role of Schlafen 11 (SLFN11) across multiple cancers	29
Checkpoint-blocker-induced autoimmunity is associated with favourable outcome in metastatic melanoma and distinct T-cell expression profiles	29
Detection of recurrences using serum miR-371a-3p during active surveillance in men with stage I testicular germ cell tumours	29
The use of hyperpolarised 13C-MRI in clinical body imaging to probe cancer metabolism	29
Cell-free DNA technologies for the analysis of brain cancer	29
A systematic review of microbial markers for risk prediction of colorectal neoplasia	29
Considering therapy-induced senescence as a mechanism of tumour dormancy contributing to disease recurrence	28
Coregulation of pathways in lung cancer patients with EGFR mutation: therapeutic opportunities	28
Phase 1b/2 trial of tepotinib in sorafenib pretreated advanced hepatocellular carcinoma with MET overexpression	28
The prognostic and diagnostic significance of the neutrophil-to-lymphocyte ratio in hepatocellular carcinoma: a prospective controlled study	28
Rationale for concurrent chemoradiotherapy for patients with stage III non-small-cell lung cancer	28
Tumour-infiltrating lymphocytes in oropharyngeal cancer: a validation study according to the criteria of the International Immuno-Oncology Biomarker Working Group	28
Genomic architecture of FGFR2 fusions in cholangiocarcinoma and its implication for molecular testing	28
Machine learning-based pathomics signature could act as a novel prognostic marker for patients with clear cell renal cell carcinoma	28
Targeting obesity-related dysfunction in hormonally driven cancers	28
Unravelling similarities and differences in the role of circular and linear PVT1 in cancer and human disease	27
Resistance to immune checkpoint therapies by tumour-induced T-cell desertification and exclusion: key mechanisms, prognostication and new therapeutic opportunities	27
Understanding the impact of sex and stage differences on melanoma cancer patient survival: a SEER-based study	27
MRI radiomics independent of clinical baseline characteristics and neoadjuvant treatment modalities predicts response to neoadjuvant therapy in rectal cancer	27
Primary tumour immune response and lymph node yields in colon cancer	27
Metastasis-directed therapy for oligometastasis and beyond	27
Folate receptor alpha in ovarian cancer tissue and patient serum is associated with disease burden and treatment outcomes	27
Inequalities in the decline and recovery of pathological cancer diagnoses during the first six months of the COVID-19 pandemic: a population-based study	27
Changes in circulating exosome molecular profiles following surgery/(chemo)radiotherapy: early detection of response in head and neck cancer patients	27
PARP inhibitors: enhancing efficacy through rational combinations	27
A highly predictive autoantibody-based biomarker panel for prognosis in early-stage NSCLC with potential therapeutic implications	27
Future perspectives of uveal melanoma blood based biomarkers	27
Immune checkpoint inhibitor combinations—current and emerging strategies	27
Randomised Phase 1b/2 trial of tepotinib vs sorafenib in Asian patients with advanced hepatocellular carcinoma with MET overexpression	27
Vitamin D supplementation and total cancer incidence and mortality by daily vs. infrequent large-bolus dosing strategies: a meta-analysis of randomised controlled trials	26
Detection of circulating tumour cells before and following adjuvant chemotherapy and long-term prognosis of early breast cancer	26
The effectiveness of the Guy’s Rapid Diagnostic Clinic (RDC) in detecting cancer and serious conditions in vague symptom patients	26
The prognostic value of combined measures of the systemic inflammatory response in patients with colon cancer: an analysis of 1700 patients	26
Prospective evaluation of 92 serum protein biomarkers for early detection of ovarian cancer	26
Application of liquid biopsy as multi-functional biomarkers in head and neck cancer	26
Combined PARP and HSP90 inhibition: preclinical and Phase 1 evaluation in patients with advanced solid tumours	26
Basal expression of RAD51 foci predicts olaparib response in patient-derived ovarian cancer xenografts	26
Retrospective analysis of Schlafen11 (SLFN11) to predict the outcomes to therapies affecting the DNA damage response	26
Benefits and harms of annual, biennial, or triennial breast cancer mammography screening for women at average risk of breast cancer: a systematic review for the European Commission Initiative on Breas	26
Simultaneous targeting of glycolysis and oxidative phosphorylation as a therapeutic strategy to treat diffuse large B-cell lymphoma	26
Circulating tumour cells and cell-free DNA as a prognostic factor in metastatic colorectal cancer: the OMITERC prospective study	26
Transitions in oral and gut microbiome of HPV+ oropharyngeal squamous cell carcinoma following definitive chemoradiotherapy (ROMA LA-OPSCC study)	25
Intravenous and subcutaneous formulations of trastuzumab, and trastuzumab biosimilars: implications for clinical practice	25
A Phase II study of neoadjuvant axitinib for reducing the extent of venous tumour thrombus in clear cell renal cell cancer with venous invasion (NAXIVA)	25
Insulin receptor substrate-1 (IRS-1) mediates progesterone receptor-driven stemness and endocrine resistance in oestrogen receptor+ breast cancer	25
Th2 cells inhibit growth of colon and pancreas cancers by promoting anti-tumorigenic responses from macrophages and eosinophils	25
Utilising extracellular vesicles for early cancer diagnostics: benefits, challenges and recommendations for the future	24
Once weekly selinexor, carfilzomib and dexamethasone in carfilzomib non-refractory multiple myeloma patients	24
Repositioning canakinumab for non-small cell lung cancer—important lessons for drug repurposing in oncology	24
METTL14-mediated N6-methyladenosine modification of Pten mRNA inhibits tumour progression in clear-cell renal cell carcinoma	24
Systemic inflammation scores correlate with survival prognosis in patients with newly diagnosed brain metastases	24
Assessing the role of cortisol in cancer: a wide-ranged Mendelian randomisation study	24
Socio-demographic variation in stage at diagnosis of breast, bladder, colon, endometrial, lung, melanoma, prostate, rectal, renal and ovarian cancer in England and its population impact	24
Breast cancer hypoxia in relation to prognosis and benefit from radiotherapy after breast-conserving surgery in a large, randomised trial with long-term follow-up	24
Ferroptosis in colorectal cancer: a future target?	24
Targeting autophagy reverses de novo resistance in homologous recombination repair proficient breast cancers to PARP inhibition	24
Recommendations from the European Commission Initiative on Breast Cancer for multigene testing to guide the use of adjuvant chemotherapy in patients with early breast cancer, hormone receptor positive	24
Early cancer diagnosis: reaching targets across whole populations amidst setbacks	24
The therapeutic and prognostic implications of immunobiology in colorectal cancer: a review	24
Clinicopathological features and BRCA1 and BRCA2 mutation status in a prospective cohort of young women with breast cancer	24
BRCA1 and BRCA2 pathogenic variants and prostate cancer risk: systematic review and meta-analysis	24
A phase 1/2 trial of ibrutinib in combination with pembrolizumab in patients with mismatch repair proficient metastatic colorectal cancer	24
Association of smoking and polygenic risk with the incidence of lung cancer: a prospective cohort study	23
Prognostic significance of esterase gene expression in multiple myeloma	23
Sodium-glucose cotransporter 2 (SGLT2) inhibitors and non-small cell lung cancer survival	23
A novel circulating miRNA panel for non-invasive ovarian cancer diagnosis and prognosis	23
Unlocking hidden potential: advancements, approaches, and obstacles in repurposing drugs for cancer therapy	23
CSNK2 in cancer: pathophysiology and translational applications	23
Transforming the landscape of early cancer detection using blood tests—Commentary on current methodologies and future prospects	23
The CBS-H2S axis promotes liver metastasis of colon cancer by upregulating VEGF through AP-1 activation	23
Radiomics predicts risk of cachexia in advanced NSCLC patients treated with immune checkpoint inhibitors	23
Topoisomerase I poison-triggered immune gene activation is markedly reduced in human small-cell lung cancers by impairment of the cGAS/STING pathway	23
CDX2 inhibits epithelial–mesenchymal transition in colorectal cancer by modulation of Snail expression and β-catenin stabilisation via transactivation of PTEN expression	23
Sensitisation of cancer cells to radiotherapy by serine and glycine starvation	23
Loss of CDX2 in colorectal cancer is associated with histopathologic subtypes and microsatellite instability but is prognostically inferior to hematoxylin–eosin-based morphologic parameters from the W	23
Reduced SKP1 and CUL1 expression underlies increases in Cyclin E1 and chromosome instability in cellular precursors of high-grade serous ovarian cancer	23
Impact of COVID-19 pandemic on eye cancer care in United Kingdom	23
Development and validation of a circulating microRNA panel for the early detection of breast cancer	23
Potential influence of the microbiome environment in patients with biliary tract cancer and implications for therapy	22
Discovery of PTN as a serum-based biomarker of pro-metastatic prostate cancer	22
Immune checkpoint inhibitors alone vs immune checkpoint inhibitors—combined chemotherapy for NSCLC patients with high PD-L1 expression: a network meta-analysis	22
Tenascin-C expression in the lymph node pre-metastatic niche in muscle-invasive bladder cancer	22
The tumour immune microenvironment in oesophageal cancer	22
Tamoxifen evolution	22
Inhibiting CBX4 efficiently protects hepatocellular carcinoma cells against sorafenib resistance	22
NTRK1 Fusions identified by non-invasive plasma next-generation sequencing (NGS) across 9 cancer types	22
CD103+CD8+ tissue-resident memory T cell infiltration predicts clinical outcome and adjuvant therapeutic benefit in muscle-invasive bladder cancer	22
The impact of COVID-19 on systemic anticancer treatment delivery in Scotland	22
The utility of ctDNA in detecting minimal residual disease following curative surgery in colorectal cancer: a systematic review and meta-analysis	22
Genetically predicted physical activity levels are associated with lower colorectal cancer risk: a Mendelian randomisation study	22
A deep convolutional neural network for segmentation of whole-slide pathology images identifies novel tumour cell-perivascular niche interactions that are associated with poor survival in glioblastoma	22
Ovarian carcinosarcoma is a distinct form of ovarian cancer with poorer survival compared to tubo-ovarian high-grade serous carcinoma	22
Ultrasound-targeted microbubble destruction remodels tumour microenvironment to improve immunotherapeutic effect	22